Since ABCB1 expression is of uncertain clinical significance in ovarian cancers, including those resistant to taxanes, in this study we developed non-MDR-resistant variants by co-exposure of a panel of ovarian cancer cell lines to a taxane plus the P-gp inhibitor PSC. Here, ABCB1 is linked to ovarian carcinoma.